ATHE Stock Analysis: Buy, Sell, or Hold?
ATHE - Alterity Therapeutics Limited American Depositary Shares
$4.67
0.22 (4.94%)
â˛
5d:
-2.51%
30d:
-0.43%
90d:
+11.72%
WAIT
LOW Confidence
Analysis Updated: Aug 21, 2026 12:00 AM ET
Earnings: Aug 27, 2026
2d
Get Alerted When ATHE Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
âšī¸ NEUTRAL: ATHE is fairly priced but lacks strong directional signals. Wait for clearer setup or better entry on dips.
âšī¸ NEUTRAL: ATHE is fairly priced but lacks strong directional signals. Wait for clearer setup or better entry on dips.
In-depth Analysis How we analyze
Valuation Analysis: ATHE is currently trading at $4.67, which is considered fair relative to its 30-day fair value range of $4.45 to $4.83.
Technical Outlook: Technically, ATHE is in a uptrend. Immediate support is located at $4.31, while resistance sits at $5.04. The stock is showing strong short-term momentum, up 4.9% recently.
Market Sentiment: ATHE scores 38/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $13.25 (+183.7%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, ATHE is in a uptrend. Immediate support is located at $4.31, while resistance sits at $5.04. The stock is showing strong short-term momentum, up 4.9% recently.
Market Sentiment: ATHE scores 38/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $13.25 (+183.7%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$4.45 -
$4.83
Company Quality Score
52/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
55.3%
All Signals
- NEUTRAL: Price in fair range
- BEARISH: Weak technical setup (38/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+4.9%)
- BULLISH: Trading 183.7% below Wall St target ($13.25)
- WARNING: Composite score 52/100 in the bottom quintile â this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$4.45 -
$4.83
Current vs Trading Range
FAIR
Support & Resistance Levels
Support Level
$4.31
Resistance Level
$5.04
Current Trend
Uptrend
Technical data as of
Aug 21, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-5.24
Wall Street Target
$13.25
(+183.7%)
Revenue Growth (YoY)
74.6%
Profit Margin
-219.9%
Share & Embed Analysis
Last updated: August 24, 2026 12:08 AM ET
Data refreshes hourly during market hours. Next update: 1:08 AM
Data refreshes hourly during market hours. Next update: 1:08 AM
đĨ Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is ATHE showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
RARE
Ultragenyx |
STRONG BUY
20 analysts |
$55 | 57 HOLD |
|
ACLX
Arcellx Inc |
STRONG BUY
18 analysts |
$113 | 50 HOLD |
|
RCKT
Rocket Pharmaceuticals IâĻ |
STRONG BUY
18 analysts |
$9 | 53 HOLD |
|
IONS
Ionis Pharmaceuticals Inc |
BUY
26 analysts |
$88 | 40 SELL |
|
ASND
Ascendis Pharma AS |
STRONG BUY
16 analysts |
$313 | 51 HOLD |
